文章摘要
李 妍,刘 虎,胡宗涛.体部伽马刀治疗结肠癌患者肝肺转移灶临床疗效观察[J].南京医科大学学报,2015,(6):833~836
体部伽马刀治疗结肠癌患者肝肺转移灶临床疗效观察
The clinical efficacy of colon cancer patients with liver and lung metastases by body gamma knife
投稿时间:2015-01-19  
DOI:10.7655/NYDXBNS20150614
中文关键词: 伽马刀  结肠癌  肝肺转移  血清癌胚抗原
英文关键词: gamma knife  colon cancer  liver and lung metastasis  serum carcino-embryonic antigen
基金项目:国家自然科学基金(81472750)
作者单位
李 妍 安徽医科大学第一附属医院肿瘤内科,安徽 合肥 230022
解放军第105医院肿瘤科,安徽 合肥 230031 
刘 虎 安徽医科大学第一附属医院肿瘤内科,安徽 合肥 230022 
胡宗涛 解放军第105医院肿瘤科,安徽 合肥 230031 
摘要点击次数: 911
全文下载次数: 591
中文摘要:
      目的:探讨体部伽马刀治疗结肠癌患者肝肺转移灶的临床疗效。方法:选取2009年1月~2011年1月解放军第105医院收治的58例发生肝肺转移的结肠癌患者,随机将其分成对照组和观察组,其中对照组28例共113个转移灶,采用单纯全身化疗治疗,观察组30例共116个转移灶,采用体部伽马刀治疗。治疗结束后比较两组患者的近期疗效,1年?2年和3年局控率和生存率?血清癌胚抗原(carcino-embryonic antigen,CEA)的变化情况以及两组患者的不良反应情况。结果:观察组患者总缓解率(84.5%)明显高于对照组患者(49.6%)(P < 0.05);观察组患者治疗后血清CEA浓度(3.8 ± 1.3)ng/mL明显低于对照组患者(7.3 ± 3.2)ng/mL(P < 0.05);观察组患者的1年(96.7%)?2年(90.0%)?3年(86.7%)局控率明显高于对照组患者(85.7%?64.3%和35.7%,P < 0.05);观察组患者的1年(73.3%)?2年(36.7%)?3年(20.0%)生存率明显高于对照组患者(64.3%,28.6%和7.1%,P < 0.05);观察组患者消化道反应?血液学毒性以及肝肾毒性发生率(20.0%?13.3%和6.7%)明显低于对照组患者(64.3%?50.0%和35.7%,P < 0.05)。结论:体部伽马刀治疗结肠癌患者肝肺转移灶临床疗效显著,安全有效,值得临床推广应用。
英文摘要:
      Objective:To investigate the clinical efficacy of colon cancer patients with liver and lung metastases by body gamma knife. Methods: During January 2009 to January 2011, 58 cases of colon cancer patients with liver and lung metastases in our hospital were randomly divided into the control group and the observation group. A total of 28 patients with 113 metastases in the control group were treated with systemic chemotherapy alone, and 30 patients with 116 metastases in the observation group were treated with body gamma knife treatment. After treatment, recent therapeutical effect, one year, two year and three-year local control rates and survival rates, serum carcino-embryonic antigen (CEA) and adverse changes of the two groups were compared. Results: The overall response rate (84.5%) of the observation group was significantly higher than that of the control group (49.6%) (P < 0.05). The serum CEA concentrations (3.8 ± 1.3 ng/ml) after treatment of the observation group was significantly lower than that of the control group (7.3 ± 3.2 ng/ml)(P < 0.05). The local control rates of one year (96.7%), two years (90.0%), three years (86.7%) of the observation group were significantly higher than those of the control group (85.7%, 64.3% and 35.7%) (all P < 0.05). The survival rates of one year (73.3%), two years (36.7%), three years (20.0%) of the observation group were significantly higher than those in the control group (64.3% , 28.6% and 7.1%) (all P < 0.05). The gastrointestinal reactions, hematologic toxicity, and liver and kidney toxicity incidence (20.0%, 13.3% and 6.7%) of the observation group were significantly lower than those of the control group (64.3%, 50.0 % and 35.7%) (all P < 0.05). Conclusion: The clinical efficacy of colon cancer patients with liver and lung metastases by body gamma knife was significantly effective, safe, and worthy of clinical application.
查看全文   查看/发表评论  下载PDF阅读器
关闭